Group 1 - The biotechnology company Valiant Biotech (09887.HK) has launched an IPO, planning to globally offer 32.0544 million shares, with 28.8489 million shares for international offering and 3.2055 million shares for public offering in Hong Kong [3] - The price range for the shares is set between HKD 31.6 and HKD 35, with an estimated net proceeds of approximately HKD 967.7 million from the global offering, assuming no exercise of the over-allotment option [3] - The public offering in Hong Kong started on July 17 and will end on July 22, with the final offer price and allocation results to be announced on July 24 [3] Group 2 - Valiant Biotech has secured nine cornerstone investors, including Tencent (00700.HK) and OrbiMed, with a total subscription amount of USD 69 million (approximately HKD 541.6 million) for the offered shares [4] - The company focuses on discovering, developing, and commercializing new therapies for cancer, autoimmune diseases, and other major diseases, with a diverse product portfolio including four core products [4] - The core product LBL-024 has entered a single-arm registration clinical trial for advanced pulmonary neuroendocrine carcinoma, expected to submit the first biological product license application to NMPA by Q3 2026 [4] Group 3 - Another major product, LBL-034, targets both GPRC5D and CD3 and received orphan drug designation from the FDA for the treatment of multiple myeloma [5] - Valiant Biotech has not yet commercialized any products and has recorded operating losses, with losses of RMB 362 million, RMB 301 million, and RMB 75.367 million for the first quarters of 2023, 2024, and 2025 respectively [5]
【IPO追踪】引入腾讯等9名基石投资者，维立志博今起招股